T
R E N D S I N
C
A R D I O V A S C U L A R
[4]
Sofuoglu M, Brown S, Babb DA, Pentel PR, Hatsukami DK. Effects of labetalol treatment on the physiological and subjective response to smoked cocaine. Pharmacol Biochem Behav 2000;65:255–9. [5] Hoskins MH, Leleiko RM, Ramos JJ, Sola S, Caneer PM, Khan BV. Effects of labetalol on hemodynamic parameters and soluble biomarkers of inflammation in acute coronary syndrome in patients with active cocaine use. J Cardiovasc Pharmacol Ther 2010;15:47–52. [6] Sofuoglu M, Brown S, Babb DA, Pentel PR, Hatsukami DK. Carvedilol affects the physiological and behavioral response to smoked cocaine in humans. Drug Alcohol Depend 2000; 60:69–76. [7] Self T, Rogers ML, Mancell J, Soberman JE. Carvedilol therapy after cocaine-induced myocardial infarction in patients with asthma. Am J Med Sci 2011;342:56–61.
ME
D I C I N E
26 (2016) 202–203
203
Öcal L, Çakir H, Tellice M, İzci S, Alizade E, Esen AM. Successful treatment of cocaine-induced cardiotoxicity with carvedilol therapy. Herz 2015;40:159–61. [9] Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61: e179–347. [10] Richards JR, Albertson TE, Derlet RW, Lange RA, Olson KR, Horowitz BZ. Treatment of toxicity from amphetamines, related derivatives, and analogues: A systematic clinical review. Drug Alcohol Depend 2015; 150:1–13. [8]
Letter to the editor response Rachel V. Stankowski, PhDa, Robert A. Kloner, MDb,n, and Shereif H. Rezkalla, MDc a
Marshfield Clinic Research Foundation, Marshfield, WI Huntington Medical Research Institutes, Pasadena, CA c Marshfield Clinic, Marshfield, WI b
We very much appreciate these comments being brought to our attention [1]. The authors are correct that in the cited study, Boehrer et al. [2] demonstrate that labetalol treatment fails to alleviate cocaine-induced coronary vasoconstriction, but does not exacerbate it. We continue to think that betablockers should be used with extreme caution in patients with cocaine-associated cardiac disease as there is always a possibility of exacerbating coronary spasms with some, but not all, beta-blockers. The authors of this letter to the editor provide a thoughtful and interesting discussion of the current state of the evidence regarding clinical use of beta-blockers in the context of cocaine-associated cardiovascular complications
and we feel that this is an excellent addition to the work we have presented.
refere nces
[1] [2]
Richards J, Lange R. Letter to the Editor. Trends Cardiovasc Med 2015 [In press]. Boehrer JD, Moliterno DJ, Willard JE, Hillis LD, Lange RA. Influence of labetalol on cocaine-induced coronary vasoconstriction in humans. Am J Med 1993;94: 608–10.
The authors have indicated there are no conflicts of interest. n Corespondence to: Huntington Medical Research Institute, Pasadena, CA 91105. Tel.: þ1 213 977 4040. E-mail address: [email protected] (R.A. Kloner).
R E N D S I N
C
A R D I O V A S C U L A R
[4]
Sofuoglu M, Brown S, Babb DA, Pentel PR, Hatsukami DK. Effects of labetalol treatment on the physiological and subjective response to smoked cocaine. Pharmacol Biochem Behav 2000;65:255–9. [5] Hoskins MH, Leleiko RM, Ramos JJ, Sola S, Caneer PM, Khan BV. Effects of labetalol on hemodynamic parameters and soluble biomarkers of inflammation in acute coronary syndrome in patients with active cocaine use. J Cardiovasc Pharmacol Ther 2010;15:47–52. [6] Sofuoglu M, Brown S, Babb DA, Pentel PR, Hatsukami DK. Carvedilol affects the physiological and behavioral response to smoked cocaine in humans. Drug Alcohol Depend 2000; 60:69–76. [7] Self T, Rogers ML, Mancell J, Soberman JE. Carvedilol therapy after cocaine-induced myocardial infarction in patients with asthma. Am J Med Sci 2011;342:56–61.
ME
D I C I N E
26 (2016) 202–203
203
Öcal L, Çakir H, Tellice M, İzci S, Alizade E, Esen AM. Successful treatment of cocaine-induced cardiotoxicity with carvedilol therapy. Herz 2015;40:159–61. [9] Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61: e179–347. [10] Richards JR, Albertson TE, Derlet RW, Lange RA, Olson KR, Horowitz BZ. Treatment of toxicity from amphetamines, related derivatives, and analogues: A systematic clinical review. Drug Alcohol Depend 2015; 150:1–13. [8]
Letter to the editor response Rachel V. Stankowski, PhDa, Robert A. Kloner, MDb,n, and Shereif H. Rezkalla, MDc a
Marshfield Clinic Research Foundation, Marshfield, WI Huntington Medical Research Institutes, Pasadena, CA c Marshfield Clinic, Marshfield, WI b
We very much appreciate these comments being brought to our attention [1]. The authors are correct that in the cited study, Boehrer et al. [2] demonstrate that labetalol treatment fails to alleviate cocaine-induced coronary vasoconstriction, but does not exacerbate it. We continue to think that betablockers should be used with extreme caution in patients with cocaine-associated cardiac disease as there is always a possibility of exacerbating coronary spasms with some, but not all, beta-blockers. The authors of this letter to the editor provide a thoughtful and interesting discussion of the current state of the evidence regarding clinical use of beta-blockers in the context of cocaine-associated cardiovascular complications
and we feel that this is an excellent addition to the work we have presented.
refere nces
[1] [2]
Richards J, Lange R. Letter to the Editor. Trends Cardiovasc Med 2015 [In press]. Boehrer JD, Moliterno DJ, Willard JE, Hillis LD, Lange RA. Influence of labetalol on cocaine-induced coronary vasoconstriction in humans. Am J Med 1993;94: 608–10.
The authors have indicated there are no conflicts of interest. n Corespondence to: Huntington Medical Research Institute, Pasadena, CA 91105. Tel.: þ1 213 977 4040. E-mail address: [email protected] (R.A. Kloner).
